61 [89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to predict WW in mccRCC patients 21. rabmaier K, Vissers JL, De Weijert MC, et al. Molecular cloning and immunogenicity of renal cell carcinomaassociated antigen G250. Int J Cancer. Mar 15 2000;85(6):865-70. 22. Oosterwijk E, Ruiter DJ, Hoedemaeker PJ, et al. Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int J Cancer. Oct 15 1986;38(4):489-94. 23. Oosterwijk E, Ruiter DJ, Wakka JC, et al. Immunohistochemical analysis of monoclonal antibodies to renal antigens. Application in the diagnosis of renal cell carcinoma. Am J Pathol. May 1986;123(2):301-9. 24. Oosterwijk-Wakka JC, Boerman OC, Mulders PF, Oosterwijk E. Application of monoclonal antibody G250 recognizing carbonic anhydrase IX in renal cell carcinoma. Int J Mol Sci. May 29 2013;14(6):11402-23. doi:10.3390/ ijms140611402 25. Boellaard R, O’Doherty MJ, Weber WA, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. Jan 2010;37(1):181-200. doi:10.1007/s00259-009-1297-4 26. Verhoeff SR, van Es SC, Boon E, et al. Lesion detection by [(89)Zr]Zr-DFO-girentuximab and [(18)F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma. Eur J Nucl Med Mol Imaging. Jun 6 2019;doi:10.1007/ s00259-019-04358-9 27. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. Jan 2009;45(2):228-47. doi:10.1016/j.ejca.2008.10.026 28. Firth D. Bias Reduction of Maximum Likelihood Estimates. Biometrika. 1993;80:27-38. doi:https://doi.org/10.1093/ biomet/80.1.27 29. Simon N, Friedman J, Hastie T, Tibshirani R. Regularization Paths for Cox’s Proportional Hazards Model via Coordinate Descent. J Stat Softw. Mar 2011;39(5):1-13. doi:10.18637/jss.v039.i05 30. Harrell FE, Jr., Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. Feb 28 1996;15(4):361-87. doi:10.1002/(sici)10970258(19960229)15:4<361::Aid-sim168>3.0.Co;2-4 31. Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. Jun 2000;56(2):337-44. doi:10.1111/j.0006-341x.2000.00337.x 32. van Kuijk SJ, Yaromina A, Houben R, Niemans R, Lambin P, Dubois LJ. Prognostic Significance of Carbonic Anhydrase IX Expression in Cancer Patients: A Meta-Analysis. Front Oncol. 2016;6:69. doi:10.3389/fonc.2016.00069 33. Rini BI, Battle D, Figlin RA, et al. The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC). J Immunother Cancer. Dec 20 2019;7(1):354. doi:10.1186/ s40425-019-0813-8 34. Bedke J, Albiges L, Capitanio U, et al. The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care. Eur Urol. May 29 2021;doi:10.1016/j.eururo.2021.04.042 35. Clark DJ, Dhanasekaran SM, Petralia F, et al. Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma. Cell. Oct 31 2019;179(4):964-983 e31. doi:10.1016/j.cell.2019.10.007 36. Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. New England Journal of Medicine. 2018;378(14):1277-1290. doi:10.1056/NEJMoa1712126 37. Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. Mar 21 2019;380(12):1116-1127. doi:10.1056/NEJMoa1816714 38. Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma. New England Journal of Medicine. 2013;369(8):722-731. doi:10.1056/NEJMoa1303989 3
RkJQdWJsaXNoZXIy MTk4NDMw